Key result
Recombinantly produced angiotensinogen from the lamprey Lampetra fluviatilis showed progressive inhibitory activity towards human α-thrombin, which was enhanced >800-fold by heparin.
No immediate clinical application; leaves open evolutionary insights into heparin-enhanced thrombin inhibition for future anticoagulant research.
Angiotensinogen is well known as source protein for a group of potent vasoactive hormones, however, a discrete biochemical activity of the angiotensinogen body is not known. Here we investigated angiotensinogen from the lamprey Lampetra fluviatilis (L. fluviatilis), an early-diverged vertebrate. The recombinantly produced protein showed progressive inhibitory activity towards human α-thrombin with a second-order rate constant of 2.6×10(4) M(-1) min(-1). Heparin enhanced the reaction rate >800-fold with a bell-shaped dose-response curve and a stoichiometry of inhibition (SI) of 1.3, revealing lamprey angiotensinogen as an effective α-thrombin inhibitor. Genomic, biochemical, and protein sequence data indicate that angiotensinogen and heparin cofactor II (HCII) originated from a common ancestral thrombin antagonist, thus providing insight into an early stage of thrombin control.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2011) studied this question. Lamprey angiotensinogen was evaluated on Inhibitory activity towards human α-thrombin (second-order rate constant of 2.6×10(4) M(-1) min(-1)). Recombinantly produced angiotensinogen from the lamprey Lampetra fluviatilis showed progressive inhibitory activity towards human α-thrombin, which was enhanced >800-fold by heparin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: